# OEC 14 2005

# 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS Troponin I Ultra (TnI-Ultra) Assay for Bayer ADVIA IMS®

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.

The assigned 510(k) number is: _K052503

# Intended Use

The ADVIA $\mathbf { I M S } ^ { \otimes }$ Troponin I Ultra (TnI-Ultra) method is for in vitro diagnostic use to quantitatively measure the cardiac Troponin I in human serum and plasma (lithium heparin). When used in conjunction with other clinical data such as presenting symptoms and diagnostic procedures, measurements of cardiac Troponin I aid in the diagnosis of acute myocardial infarction (AMI) and in the risk stratification of patients with non-ST segment-elevation, acute coronary syndromes with respect to relative risk of mortality, myocardial infarction, or increased probability of ischemic events requiring urgent revascularization procedures.

# Predicate Device

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent REF</td><td rowspan=1 colspan=1>Calibrator REF</td></tr><tr><td rowspan=1 colspan=1>Bayer ACS:180® cTnI Assay</td><td rowspan=1 colspan=1>07572636 (50 tests)00370639 (300 tests)</td><td rowspan=1 colspan=1>Included with Reagents</td></tr></table>

# Device / Method

<table><tr><td rowspan=1 colspan=1>Product Name</td><td rowspan=1 colspan=1>Reagent REF</td><td rowspan=1 colspan=1>Calibrator REF</td></tr><tr><td rowspan=1 colspan=1>ADVIA IMS Troponin IUltra (TnI-Ultra) Assay</td><td rowspan=1 colspan=1>02157487</td><td rowspan=1 colspan=1>06504521</td></tr></table>

# 4. Imprecision

<table><tr><td rowspan=1 colspan=2>ADVIA IMS TnI-UltraAssay</td></tr><tr><td rowspan=1 colspan=1>Level(ng/mL)</td><td rowspan=1 colspan=1>Total CV(%)</td></tr><tr><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>14.06</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>32.93</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>9.05</td><td rowspan=1 colspan=1>2.7</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Bayer ACS:180 cTnI Assay</td></tr><tr><td rowspan=1 colspan=1>Level(ng/mL)</td><td rowspan=1 colspan=1>Total CV(%)</td></tr><tr><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>15.73</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>33.83</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>43.01</td><td rowspan=1 colspan=1>5.8</td></tr></table>

# Correlation $\mathbf { Y } { = }$ ADVIA IMS®, $\mathbf { X } =$ Bayer ACS:180)

<table><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>ComparativeSystem (X)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Syx(ng/mL)</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>SampleRange(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Serum(Passing Bablok)</td><td rowspan=1 colspan=1>BayerACS:180</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>1.01 *X - 0.01</td><td rowspan=1 colspan=2>N/A</td><td rowspan=1 colspan=1>0.01 to 49.6</td></tr><tr><td rowspan=1 colspan=1>Serum(Linear Regression)</td><td rowspan=1 colspan=1>BayerACS:180</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>0.90 * X + 0.43</td><td rowspan=1 colspan=1>2.64</td><td rowspan=1 colspan=1>0.954</td><td rowspan=1 colspan=1>0.01 to 49.6</td></tr></table>

# 6Interfering substances

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>InterferenceConc.</td><td rowspan=1 colspan=2>Recovery(ng/mL)</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Interference</td><td rowspan=1 colspan=1>mg/dL</td><td rowspan=1 colspan=1>Expected</td><td rowspan=1 colspan=1>Observed</td><td rowspan=1 colspan=1>Deviation</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>6500</td><td rowspan=1 colspan=1>9.32</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>22.9</td><td rowspan=1 colspan=1>20.6</td><td rowspan=1 colspan=1>-3.3</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>22.9</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>-4.7</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>22.7</td><td rowspan=1 colspan=1>20.1</td><td rowspan=1 colspan=1>-3.8</td></tr></table>

# 7. Analytical Range

$0 . 0 1 ~ \mathrm { \mathfrak { n g / m L } }$ EY $( 0 . 0 1 ~ \mu \mathrm { g / L } )$ to $5 0 \ \mathrm { n g / m L } \left( 5 0 \mu \mathrm { g / L } \right)$

# 8. Minimum Detectable Concentration

<table><tr><td>ADVIA IMS TnI- Ultra (ng/mL)</td><td>Bayer ACS:180 cTnl (ng/mL)</td></tr><tr><td>0.01</td><td>0.10</td></tr></table>

# 9. ${ \mathfrak { g } } { \mathfrak { g } } ^ { { \mathfrak { t h } } }$ Percentile Distribution and Functional Sensitivity

Based on 337 serum samples from apparently healthy donors, the upper $9 9 ^ { \mathfrak { t h } }$ percentile Troponin I value is $0 . 0 4 ~ \mathrm { { n g / m L } }$ .

Functional Sensitivity $10 \%$ total C.V.) is $0 . 0 3 ~ \mathrm { n g / m L }$ for ADVIA $\mathbf { I M S } ^ { \otimes }$ TnI-Ultra Assay.

# 10. Expected Results

The AMI cutoff value is based on the data for the Bayer HealthCare ACS:180 Troponin I assay, to which ADVIA $\mathrm { I M S } ^ { \mathfrak { G } }$ TnI-Ultra method is equivalent.

<table><tr><td>Sample</td><td>N</td><td>Range μg/L (ng/mL)</td></tr><tr><td>Healthy Blood Donors</td><td>337</td><td>&lt;0.04</td></tr><tr><td>AMI patients</td><td>112</td><td>≥ 1.5</td></tr></table>

# DEC 14 2005

Mr. Andres Holle   
Manager, Regulatory Affairs   
Bayer HealthCare Diagnostics Division   
511 Benedict Avenue   
Tarrytown, NY 10591

Re: k052503 Trade/Device Name: Troponin 1 Ultra Assay and Calibrator for the ADVIA IMS $\textsuperscript { \textregistered }$ System Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system Regulatory Class: Class II Product Code: MMI, JIT Dated: November 7, 2005 Received: November 9, 2005

Dear Mr. Holle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification.The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/1de9345b74030af8f97acbe00ae225ced3bef11ffccc3e82601e09821a50da93.jpg)

Alberto Gutierez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

Device Name: Troponin I Ultra Assay and Calibrator for the ADVIA IMS® System

Indications For Use:

The ADVIA ${ \mathsf { I M S } } ^ { \otimes }$ Troponin I Ultra (Tnl-Ultra) method is for in vitro diagnostic use to quantitatively measure the cardiac Troponin I in human serum and plasma (lithium heparin). When used in conjunction with other clinical data such as presenting symptoms and diagnostic procedures, measurements of cardiac Troponin I aid in the diagnosis of acute myocardial infarction (AMl) and in the risk stratification of patients with non-ST segment-elevation, acute coronary syndromes with respect to relative risk of mortality, myocardial infarction, or increased probability of ischemic events requiring urgent revascularization procedures.

The ADVIA ${ 1 \ M \mathbb { S } } ^ { \otimes }$ Tnl-Ultra Calibrator is for the in vitro diagnostic use in the calibration of the Tnl-Ultra assay on the ADVIA ${ \mathsf { I M S } } ^ { \circledast }$ system

Prescription Use (Part 21 CFR 801 Subpart D)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Carol eneom A 5 Page 1 of 31K052503